Clinical Trials
5 trialsNCT04662255 2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05024045 2026-03-03
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04849416 2026-02-06
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company
Phase 2 Completed
NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
NCT05172700 2024-12-18
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Eli Lilly and Company
Approved for marketing